Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction

BMJ Open

Volumn 4, Issue 10, 2014, Pages

  Mortensen, Martin B ^a   Falk, Erling ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AMERICAN; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; EUROPEAN; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PRIMARY PREVENTION; QRISK SCORE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; ALGORITHM; BLOOD; CARDIOVASCULAR DISEASES; EUROPE; MEDICAL SOCIETY; MIDDLE AGED; MYOCARDIAL INFARCTION; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ADULT; AGED; ALGORITHMS; AMERICAN HEART ASSOCIATION; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EUROPE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84908139263     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005991     Document Type: Article

References (33)

1. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635-701.
2. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S49-73.
3. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45.
4. National Institute for Health and Care Excellence (NICE) Clinical Guideline CG181: Lipid modification - Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. National Clinical Guideline Centre, July 2014. http://www.nice.org.uk/Guidance/cg181 (accessed 26 July 2014).
5. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease ( JBS3). Heart 2014;100 (Suppl 2):ii1-67.
6. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38.
7. Mortensen MB, Sivesgaard K, Jensen HK, et al. Traditional SCORE-based health check fails to identify individuals who develop acute myocardial infarction. Dan Med J 2013;60:A4629.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults final report. Circulation 2002;106:3143-421.
9. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
10. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
11. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham study. Ann N Y Acad Sci 1963;107:539-56.
12. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979;110:281-90.
13. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988;41:1105-16.
14. Investigators TA. The Atherosclerosis risk in communities (ARIC) study: design and objectives. Am J Epidemiol 1989;129:687-702.
15. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263-76.
16. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.
17. ESC HeartScore risk calculator. http://www.heartscore.org (accessed 27 May 2014).
18. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol 2009;54:1209-27.
19. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 2010;121:1768-77.
20. Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-8.
21. Lloyd-Jones DM, Goff D, Stone NJ. Statins, risk assessment, and the new American prevention guidelines. Lancet 2014;383:600-2.
22. Robinson JG. Accumulating evidence for statins in primary prevention. JAMA 2013;310:2405-6.
23. Ioannidis JP. More than a billion people taking statins? - potential implications of the new cardiovascular guidelines. JAMA 2014;311:463-4.
24. Deaño RC, Pandya A, Jones EC, et al. A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines. Curr Atheroscler Rep 2014;16:438.
25. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422-31.
26. Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014;311:1416-23.
27. Jackson R, Kerr A, Wells S. Vascular risk calculators: essential but flawed clinical tools? Circulation 2013;127:1929-31.
28. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013;382:1762-5.
29. Capewell S, O'Flaherty M. Rapid mortality falls after risk-factor changes in populations. Lancet 2011;378:752-3.
30. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA 2014;311:1406-15.
31. Ridker PM, Danielson E, Fonseca F, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
32. Pitt B, Loscalzo J, Ycas J, et al. Lipid levels after acute coronary syndromes. J Am Coll Cardiol 2008;51:1440-5.
33. Hawkes N. NICE sticks to its advice to drop threshold for prescribing statins. BMJ 2014;349:g4694.